CardiNor Leads The Charge As Norway Gets Behind Life Sciences
Executive Summary
Norwegian start-up CardiNor is developing a new cardiovascular biomarker, and is hopeful of attracting cash in a country where investor traditions are undergoing some changes. The financial pressures caused by falling oil prices have brought renewed attention to life science companies.
You may also be interested in...
Start-Up Quarterly Statistics, Q1 2016
Start-ups raised $1.8 billion in Q1 2016. Biopharma companies penned 33 alliances; 14 acquisitions were signed (11 in the biopharma industry).
Algeta, Aspiring For Solo Success, Draws Bayer Bid After Xofigo Launch
The Norwegian biotech is keen to show it is not a one-trick pony, but its future might lie in the embrace of its big pharma partner Bayer.
Seven Trending Technologies On The Cusp Of Mainstream Uptake
At HIMSS22, NEO.Life’s Jane Metcalfe identified seven trending technologies that are set to move from the fringes of medicine to the center of attention.